U.S. FDA’s Tropical Disease Priority Review Voucher Fee Set at $2.7 Million

International Pharmaceutical Regulatory Monitor
A A
Drugmakers submitting an NDA or BLA with a tropical disease priority review voucher in the U.S. will now pay a $2.7 million fee — a $165,000 increase over fiscal year 2015, which ended Sept. 30.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00